Phathom Pharmaceuticals (PHAT) Assets Average (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Assets Average data on file, last reported at $282.1 million in Q1 2026.

• On a quarterly basis, Assets Average fell 16.1% year-over-year to $282.1 million in Q1 2026; TTM through Mar 2026 was $282.1 million, a 16.1% decrease from a year earlier, with the FY2025 full-year figure at $318.7 million, down 19.53% from the prior year.
• Assets Average for Q1 2026 stood at $282.1 million, up from $249.7 million in the prior quarter.
• Over the last five years, Assets Average for PHAT reached as high as $385.2 million in Q1 2024 and fell as low as $154.4 million in Q1 2023.
• Historically, Assets Average has averaged $266.0 million across 5 years, with a median of $251.0 million in 2023.
• Across the five-year window, Assets Average plunged 37.49% in 2022 and jumped 149.45% in 2024, its largest moves.
• Year by year, Assets Average stood at $183.4 million in 2022, then jumped by 77.46% to $325.4 million in 2023, then rose by 17.6% to $382.7 million in 2024, then slumped by 34.74% to $249.7 million in 2025, then gained by 12.98% to $282.1 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $282.1 million in Q1 2026, $249.7 million in Q4 2025, and $245.3 million in Q3 2025.